Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (K_d: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis.

Tildrakizumab 抑制表达人 IL-23Rα 和 IL-12Rβ1 受体的 HeLa 细胞中 IL-23 诱导的 STAT3 信号，IC₅₀ 为 23 pM。
Tildrakizumab 通过负变构调节降低 IL-23 对 IL-23Rα 的亲和力。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Tildrakizumab (100 mg/kg，皮下注射，每 2 周一次，最多 9 个月) 在食蟹猴中具有良好的耐受性 (毒性研究)。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Tildrakizumab (100 mg/kg，皮下注射，每 2 周一次，最多 9 个月) 在食蟹猴中具有良好的耐受性 (毒性研究)。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.  [Content Brief]

  . Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420.  [Content Brief]

  . Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476.  [Content Brief]